Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

v3.24.1
Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Significant Accounting Policies [Abstract]  
Schedule of Depreciable Rates of Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:
    %   Mainly
%		  
           
Laboratory equipment   10     10  
             
Computers, office furniture and equipment   6 - 33     33  
Schedule of Major Customer Data as a Percentage of Total Revenues Major customer data as a percentage of total revenues:
    Year ended December 31,  
    2023     2022     2021  
                   
Cipher Pharmaceuticals (Canada)     11 %     11 %     12 %
Chong Kun Dang Pharmaceuticals Corp. (South Korea)     25 %     25 %     24 %
Gebro Holding GmbH (Austria)     18 %     18 %     23 %
Ewopharma AG (Switzerland)     46 %     46 %     41 %
                         
Total     100 %     100 %     100 %
Schedule of Antidilutive Shares All outstanding share options and warrants for the years ended December 31, 2023, 2022 and 2021 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. The potential shares of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:
    Year ended December 31,  
    2023     2022     2021  
                   
Options     82,477,000       27,002,200       18,422,700  
Warrants     1,852,010,606       375,197,640       377,947,640  
                         
Total     1,934,487,606       402,199,840       396,370,340